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Abstract: Ovarian cancer remains one of the most common causes of death among gynecological
malignancies afflicting women worldwide. Among the gynecological cancers, cervical and endome-
trial cancers confer the greatest burden to the developing and the developed world, respectively;
however, the overall survival rates for patients with ovarian cancer are worse than the two afore-
mentioned. The majority of patients with ovarian cancer are diagnosed at an advanced stage when
cancer has metastasized to different body sites and the cure rates, including the five-year survival,
are significantly diminished. The delay in diagnosis is due to the absence of or unspecific symptoms
at the initial stages of cancer as well as a lack of effective screening and diagnostic biomarkers that
can detect cancer at the early stages. This, therefore, provides an imperative to prospect for new
biomarkers that will provide early diagnostic strategies allowing timely mitigative interventions.
Glycosylation is a protein post-translational modification that is modified in cancer patients. In
the current review, we document the state-of-the-art of blood-based glycomic biomarkers for early
diagnosis of ovarian cancer and the technologies currently used in this endeavor.
Keywords: ovarian cancer; biomarker; clinical biomarker; glycan
1. Introduction
In 2018, the Global Cancer Observatory GLOBOCAN reported an estimate of 295,414
ovarian cancer (OvCa) cases out of the total incidences of female cancers of about 8.8 million
globally. Of the total incidences of death from female cancers of 4.1 million globally,
184,799 mortalities were from ovarian cancer. Further predictions indicate a worldwide
increase of OvCa incidences to 404,268 and 268,302 deaths by the year 2035 [1]. OvCa
exhibits a high amount of heterogeneity by the very nature of their histological or molecular
origin. OvCas are classified into five major types based on their histological and molecular
genetics. They are high-grade serous type, which is the most abundant, followed by
endometrioid, clear cell, mucinous and the least abundant, the low-grade serous ovarian
carcinoma [2,3].
The importance of diagnosing OvCa while still in its early stages is underscored by
the benefits accrued to the patient that include increased chances of successful cure or
prolonged survival period. A diagnosis made in the early stages allows sufficient duration
of time to institute various mitigative therapeutic approaches with a 90% chance of cure [4].
Past research findings have shown that about 90% of patients diagnosed with stage I OvCa
have a 5-year survival rate. Unfortunately, only about 30% of the women are diagnosed
with stage I OvCa, whereas the majority are diagnosed in stages III and IV, with reduced
5-year survival rates of 20% and 6%, respectively. Important to note is that the patient’s
survival rate has a strong correlation with the stage of the disease at which the diagnosis is
made [5,6].
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Diagnosis of OvCa in its early stage is impeded by the very nature of its unspecific
symptoms whereby in the majority of cases, signs and symptoms become only clear when
the tumor is in its advanced stages (FIGO Stage III and IV) [4,5]. Moreover, the lack of
effective screening and early diagnostic strategies that can detect OvCa in its formative
stages, before manifestation of full-blown symptoms, has been the missing link in the
fight to reduce the mortalities associated with late-stage diagnosis [7]. Introduction of
new, effective and less-invasive biomarkers that will help to detect OvCa promptly are,
therefore, urgently needed.
Glycosylation is an essential protein’s post-translational modification that is defer-
entially reflected in an individual’s health or pathological status. Glycans are made up
of monosaccharides that are linked by glycosidic bonds in many different ways to form
highly branched structures, hence they exhibit enormous heterogeneity. This is in contrast
to the highly conserved template-driven DNA and proteins [8]. Aberrant modifications of
glycans have been reported for many forms of cancer and they correlate with the overex-
pression of enzymes that are responsible for the biological processing of glycans, namely
glycosidases and glycosyltransferases [9]. They are usually protein-specific, cell-specific,
site-specific and their mechanisms have been studied in detail; for a review, see [10]. In
human blood, all proteins, except albumin, are glycosylated. N-Glycosylation occurs at
the side chain of asparagine residues in nascent glycoproteins according to the consensus
motif asparagine-X-serine/threonine, where X can be any amino acid except proline, while
O-glycans are linked to the hydroxyl group of serine or threonine.
In the following, we review the clinically approved glycan-based biomarkers for
OvCa, the milestones achieved in the ongoing glycomics research, as well as the state of
technology used in the field and the challenges encountered.
2. Clinically Approved Blood-Based Glycan Biomarkers for Ovarian Cancer
Cancer antigen-125 (CA125) is a glycoprotein blood-based biomarker used for the de-
tection of OvCa. It was clinically approved in 1981 and it is the major OvCa biomarker used
routinely in clinical settings. However, CA125 is unreliable for the detection of early stage
OvCa due to its associated limitations of low sensitivity and specificity. Other glycoprotein-
based tests that have since received clinical approvals include human epididymis 4 (HE4),
carbohydrate antigen 19-9 (CA19-9), and multi-parametric assays such as the risk of ovar-
ian malignancy algorithm (ROMA), OVA1 and OVA2 [4,11,12] (Table 1). Multi-parametric
tests find their clinical utility mostly in the risk stratification of the subjects into low- or
high-risk groups.
2.1. CA125 (MUC16)
The CA125 mucin is a highly N- and O-glycosylated transmembrane glycoprotein
expressed in the epithelium of Müllerian and coelomic types, namely ciliated cells, en-
dometrium, endocervix and pericardium, peritoneum, mesothelial cells of the pleura,
respectively [6]. The current CA125 automated ELISA test uses a combination of two
monoclonal antibodies OC125 and M11 generated against non-overlapping domains of
CA125 [13]. The concentration of more than 35 U/mL are suggestive of a possible ovarian
malignancy [14,15]. It is the most widely studied blood-based biomarker for ovarian cancer
and has been the gold standard routine biomarker for ovarian cancer ever since its approval
by the FDA in 1981 [16] (Table 1). However, CA125 is neither specific nor sensitive as a diag-
nostic marker for ovarian cancer because it is found to be elevated in gynecological benign
diseases affecting pre-menopausal women as well as in conditions such as liver cirrhosis
and heart failure, thereby limiting its applicability as a biomarker for OvCa [4,15,17,18].
Furthermore, fluctuations in CA125 levels are also evident in physiological conditions such
as pregnancy and menstruation hence, negating its importance as a diagnostic marker for
OvCa [18,19]. Of importance to note is that about 20% of the epithelial OvCa cases of serous
origin do not show overexpression of CA125 hence, the likelihood to miss out such cases
when CA125 is used as the only biomarker [20,21]. The meta-analysis study of Ferraro
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et al., revealed an overall sensitivity of 79% and specificity of 78% [16]. Mixed results have
been reported by subsequent studies [22,23]. CA125 is, therefore, neither a definitive test
that meets expectations of an accurate early diagnostic marker for ovarian cancer nor a
reliable screening tool for the general population. However, it is highly recommended
for monitoring the effectiveness of the treatment responses and detection of relapse in the
remission period by conducting serial measurements [4].
Table 1. Clinically approved glycosylated ovarian cancer biomarkers.





CA 125 Proteinconcentration 79–94 59–82
Monitoring therapy
and relapse 1981 [16,22,23]
HE4 Proteinconcentration 64–71 85–96
Monitoring therapy
and relapse 2008 [12,22,24]
CA 1-9 Proteinconcentration 50–53 84–97
Monitoring therapy
and relapse 2002 [25,26]
ROMA test Proteinconcentration 91–94 75–84 Prediction 2011 [18,22,27]
OVA1 test Proteinconcentration 77–96 28–35 Prediction 2009 [28,29]
OVA2 (Overa) Proteinconcentration 91 69 Prediction 2016 [30]
2.2. Human Epididymis 4 (HE4)
Human epididymis protein 4 (HE4), a secretory product of the WFDC2 gene, is a
glycoprotein that originates from the epithelial cells of the human epididymis, which is
overexpressed in ovarian tumors [18,28]. It is an 11 kDa small secretory glycoprotein with
hydrophobic amino acids at the terminus, expressed in patients with endometrioid, clear
cell, epithelial, and mucinous ovarian cancers [31]. HE4 was approved by the FDA in
2008 for use in monitoring patients with an established diagnosis of ovarian cancer but
not for screening early stage OvCa in asymptomatic women [6]. Unlike CA 125, HE4
values are upregulated in mucinous ovarian malignancy, giving it a wide detection scope
for the subtypes of OvCa. Furthermore, its values are not influenced by common benign
gynecological and medical conditions, as is the case with CA 125, hence they are better
in terms of specificity [31]. Moreover, previous research findings demonstrated that the
HE4 level is elevated in over 50% of ovarian tumor cases, which otherwise show normal
expression of CA 125. Hence, HE4 exhibits superior sensitivity and specificity for detecting
early stage OvCa as well as discriminating OvCa from benign ovarian tumors compared
to CA 125. HE4 also performs better in premenopausal women as well, compared to
CA125 [20,28,32].
When CA125 and HE4 tests were used as a dual marker, improved diagnostic perfor-
mance characteristics were registered. Moore et al. reported the analysis of the combined
premenopausal and postmenopausal patients with benign neoplasms, or with cancer or
low malignant potential (LMP) tumors using the dual marker algorithm, and found a
sensitivity of 86% at a specificity of 74.7%. While using the dual marker in postmenopausal
women, a sensitivity of 92.5% at a specificity of 74.7% was reported and finally, in pre-
menopausal women only, a sensitivity of 67.4% and specificity of 74.8% was obtained [18].
When distinguishing benign ovarian tumor from early stage ovarian cancer, Nolen et al.
reported improved sensitivity and specificity of 74.2% and 85%, respectively, when CA125
and HE4 tests were used as a dual test [33]. Moore et al. reported a sensitivity of 72.9% at a
specificity of 95% for the HE4 test when used alone to discriminate benign ovarian tumors
from OvCa. While at the same specificity of 95%, CA125 produced a sensitivity of 43.3%.
Improved sensitivity of 76.4% at a specificity of 95% was reported when the two tests were
done as a combination [12].
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2.3. CA 19-9
Carbohydrate antigen 19-9 (CA19-9) is a tetrasaccharide carbohydrate also named sia-
lyl Lewisa (N-acetylneuraminic acid-α2-3-galactose-β1-3[fucoseα1–4]-N-acetylglucosamine)
that belongs to the larger family of mucinous markers secreted by human pancreatic and
biliary ductal cells. Other sources of CA19-9 secretion are colon, gastric, endometrial
and salivary epithelia [34]. CA19-9 is an established marker for pancreatic ductal ade-
nocarcinoma, which received FDA approval in 2002. It is also found to be elevated in
ovarian tumors, particularly the mucinous type [26,34]. However, its clinical utility is
hampered by its insufficient sensitivity and specificity to discriminate early cancer from
benign diseases [34,35]. One of the reasons for this is that α1-4-fucosyltransferase is not
produced by about 6% of Caucasians and 22% of non-Caucasians [34]. A number of studies
have suggested the use of serum CA-19-9 as a diagnostic marker for benign dermoid cysts,
where they were successfully correlated with the tumor size, bilateral tumor involvement,
and tumor torsion with CA19-9 values [36,37]. To this end, various studies have shown
mixed results of CA19-9 analytical performance as a marker of OvCa. Santotoribio et al.
reported a sensitivity of 50% with a specificity of 97% for the CA125. When they used
CA19-9 and CA125 as a dual marker, an improved sensitivity of 66.7% at a specificity of
95% were obtained [25]. In another study, CA19-9 was able to detect mucinous ovarian
cancer with a sensitivity and specificity of 52.7% and 83.8%, respectively [26]. Although
previous studies have shown the usefulness of CA19-9 in predicting ovarian neoplasm
of mucinous type, it was unable to differentiate benign, from borderline or malignant
tumors [38].
2.4. Risk of Ovarian Malignancy Algorithm (ROMA)
ROMA is a multi-variable screening test designed by Moore et al. and approved by the
FDA in 2011 for predicting the risk of ovarian malignancy in women presenting with pelvic
masses [27]. It is a combination of CA125, HE4 and the menopausal status of the subject.
Using this score, patients presenting with pelvic masses are categorized either as high or
low risk to malignancy [27]. ROMA produced impressive performance characteristics for
detecting ovarian cancer in a combined analysis of the pre-and postmenopausal women
with a sensitivity of 93.8% and specificity of 74.9% [27]. In another study that involved
patients with invasive and borderline ovarian cancer, ROMA produced overall sensitivity
and specificity of 93.8% and 74.9%, respectively. On the other hand, premenopausal
patients had a sensitivity of 100% and a specificity of 74.2% for detecting OvCa, while the
postmenopausal had a sensitivity of 92.3% and a specificity of 76% [27]. Subsequent studies
have provided mixed results [22,39,40].
2.5. OVA1
The OVA1 screening strategy is also a multi-variable index biomarker approved by
the FDA in 2009 to distinguish malignancy from pelvic masses. It is a combination of
five serum protein assays namely, second-generation CA 125-II, transthyretin, transferrin,
β-2-microglobulin, and apoliprotein A1. The OVA1 test is useful in the stratification of
the patients as low- or high-risk groups in terms of developing ovarian cancer [11,28,41].
OVA1 achieves its optimal potential when used as an add-on to physical examination
and imaging. Improved sensitivity of 96% and a specificity of 35% were obtained when
OVA1 was used along with the physical assessment of the patient by the physician [28].
Subsequent studies produced mixed performance characteristics [29].
2.6. OVA2
OVA2, also called Overa, is the second-generation test for OVA1. OVA2 is a multi-
parametric test that stems from a combination of CA 125-II, HE4, apoliprotein A1, trans-
ferrin, and follicle-stimulating hormone. Coleman et al. reported improved performance
characteristics from that of OVA1 with a sensitivity and specificity of 91% and 69%, respec-
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tively [30]. As a result, the FDA-approved Overa test in 2016 for screening women with
pelvic masses, for either high or low risk of developing ovarian cancer [11].
3. Glycomics Methodologies
Glycomic studies can be approached at three different levels; by analysis of the free
glycans, glycopeptides, or intact glycoprotein. The choice of the approach or strategy to use
is dependent on various factors such as the nature and purity of the sample, level of tech-
nology vis-à-vis expert knowledge, and most importantly, the nature of information being
sought. In general, glycan analysis consists of the isolation of free glycans or glycopeptides.
3.1. N-Glycan Profiling
Analysis of the released glycans is preferred when seeking to understand the com-
positional and structural characteristics of the total N-glycome. This is because of their
conferred lower degree of complexity compared to glycopeptide or intact glycoprotein
samples. Glycoproteins are deglycosylated either enzymatically or chemically. The tertiary
structure of glycoproteins is first disrupted using proteases and/or denaturing reagents in
order to make the glycosylation sites accessible. Enzymatic deglycosylation is achieved
by treating a glycoprotein with endoglycosidases, preferably peptide-N-glycosidase F
(PNGase F), which hydrolyzes the amide bond of the asparagine side chain for all types
of N-glycans, except for those being α1-3 core-fucosylated. Endo H is used to specifically
remove the high-mannose and hybrid structures [42]. On the other hand, Endo S is com-
monly used in immunological research questions as it specifically releases N-glycans of
immunoglobulins (Ig) at asparagine-297 between the two N-acetylglucosamine (GlcNAc)
of their reducing end [43]. Moreover, N- and O-glycans could also be released chemically,
either separately or as a mixture of both, by hydrazinolysis through cleavage of the amide
bonds under controlled conditions [44,45]. Alternatively, β-elimination is another chemical
approach used to release both N- and O-glycans from the glycoprotein, but this technique is
mostly employed on de-N-glycosylated proteins to release the remaining O-glycans. Sialic
acids that terminate glycans can then be stabilized using permethylation, peracetylation, or
dimethylamidation [45–48], which also improves ionization efficiency through increased
sample volatility. Alternatively, the free reducing end of N-glycans may be labeled with a
fluorescent tag, thereby increasing the sensitivity as well as the limit of quantitation and
detection [45].
3.2. Glycopeptide Profiling
Glycopeptide analysis is the only bottom-up strategy that allows studying site-specific
glycosylation. In other words, simultaneous analysis of glycan structures and the peptides
they are bound on [49,50]. Prior to that, glycoproteins of interest are enriched using
specific proteins or antibodies [51–53]. IgG, the most abundant immunoglobulin in human
circulation is one of the most reported glycan-based biomarkers. Individual IgG subclass
isolation consists of consecutive affinity purification using Protein A and/or Protein G.
Protein A captures IgG1, IgG2 and IgG4, while Protein G, which is capable of capturing all
IgG subclasses, can be applied at last to capture IgG3, after IgG1, IgG2 and IgG4 have been
bound by protein A [54]. The resultant IgG preparation is then proteolytically digested by
trypsin into glycopeptides, followed by purification using hydrophilic interaction liquid
chromatography. Glycopeptide samples are subsequently profiled by mass spectrometry
either in their native form or with derivatized sialic acids [52,54,55].
3.3. Profiling of Intact Glycoproteins
This middle-up approach is broadly used in research laboratories, clinical chemistry
laboratories for routine diagnostics, or by pharmaceutical companies for product quality
controls. Target proteins are analyzed either directly without purification or isolated by
immuno-purification using specific antibodies prior to analysis [52,56–58]. Thereafter,
glycoforms are analyzed by capillary electrophoresis, and also capillary electrophoresis
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coupled to mass spectrometry and hydrophilic interaction liquid chromatography coupled
to mass spectrometry [57,59,60]. Clinical chemistry laboratories use the glycoforms of
transferrin as a marker for alcohol abuse in adults and to detect congenital disorders of
glycosylation in newborns [60]. The quality of biopharmaceuticals such as therapeutic
antibodies, interferon-beta-1a, and human erythropoietin are verified after purification of
the recombinant products [57,59]. Alternatively, intact glycoproteins can be purified with
lectins, which are glycan-binding proteins. Glycoproteins resulting from the lectin pull-
downs can be digested with proteases prior to analysis of the resulting glycopeptides [61].
3.4. Advances in High-Throughput Sample Preparation
The standard sample deglycosylation protocol using PNGase F enzymatic digestion
takes about a day due to a time-consuming N-glycan cleavage step. The major improvement
of high-throughput workflows lies in the fact that analytical turnaround times are reduced
significantly. High-throughput workflows do not only reduce the time of analysis, they also
significantly improved robustness and repeatability by introducing automation. They also
support large-scale glycan analyses in 96- or 384-well-plates, which fosters compatibility
between glycomics and clinical diagnosis [62,63].
Kronewitter and co-workers developed a high-throughput workflow for serum and
plasma, where a microwave reactor was applied to hasten PNGase F digestion. Purification
was subsequently performed using automated graphitic carbon solid-phase extraction and
later subjected to mass spectrometric measurements of the N-glycans. Microwave-assisted
N-glycan release takes about 10 min to achieve comparable levels of N-glycan release
to the standard 16 h protocol [64]. Szabo et al. used the pressure-cycling technology to
achieve the rapid release of glycoprotein N-glycans by PNGase F digestion. Pressure
cycling technology alters protein conformation by forcing water molecules into the interior
of proteins, causing them to unfold. On the other hand, cyclization between high and
atmospheric pressure was shown to enhance the probability of endoglycosidase accessing
the digestion site as a result glycan release is hastened [65]. In another approach, a reactor
with immobilized PNGase F on monolithic polymer support in a capillary was used to
allow the rapid and efficient release of N-glycans from IgG. Complete deglycosylation was
achieved in 5.5 min at room temperature. The optimized reactor could also be integrated
into a multidirectional system that is comprised of online glycan release, chromatographic
separation and the mass spectrometric measurement [64,66]. Similarly, high-throughput
96-well plate protocols were developed for the isolation and analysis of IgG [54,67] and
more recently, for IgA [54,67,68].
3.5. Analytical Instrumentation
There has been massive technological advancement in the last decade that led to the
development of high-throughput methods. The most commonly used technologies include
capillary electrophoresis (CE), ultra-performance liquid chromatography (UPLC) and mass
spectrometry (MS).
Capillary electrophoresis is a relatively recent analytical platform for profiling labeled
glycans. Glycan migration is mediated by an electric field, leading to the separation of
positional glycan isomers and quantification can be achieved using labeled maltose [69,70].
The advantage of this technique is that it has high separation power, only requiring a small
sample amount and with a quick turnaround time [71]. Glycan separation can also be
performed on UPLC via hydrophilic interaction and fluorescence detection. Just like in CE,
it is possible to resolve glycan isomers by UPLC. Retention times are standardized using
an external glucose ladder [63] and a repertoire of elution positions for glycans has been
made publicly available [72].
MS instruments are broadly used as well for glycomic studies. An MS instrument is
made up of an ion source, which energizes the analyte, a mass analyzer that sorts the ions
based on their m/z ratios, and a detector, which quantifies the resultant ions into a mass
spectrum that is a plot of the relative abundance of the ions m/z ratio. Matrix-assisted laser
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desorption/ionization time-of-flight (MALDI-TOF) is a stand-alone instrument majorly
used in the quantification of glycans or glycopeptides released chemically or enzymatically
from the parent glycoprotein. It is the most frequently used soft ionization MS platform
in glycobiology not only because of its good sensitivity but also due to its comprehensive
analytical output. Several established research groups have extensively used this method
in the sub-discipline of OvCa glycan biomarker discovery [73–78]. Unlike MALDI-TOF,
UPLC or nano LC coupled electrospray ionization are used with mass analyzers such
as quadrupole time of flight, orbitrap and Fourier transform ion cyclotron resonance
mass analyzers.
The choice of one analyzer over the other depends on the analytical problem at hand.
The factors that are considered in choosing the appropriate analyzer to use are the mass
range, laser power, resolution, sensitivity, and ion transmission of the analyzer [79,80].
4. N-Glycosylation Traits Modulated in Human Serum of Ovca Patients
4.1. Total N-Glycome
Aberrant modifications of glycans have been reported for many forms of cancer and
always correlate with overexpression of enzymes that are responsible for their biological
processing, namely glycosidases and glycosyltransferases, but also the sugar nucleotide
donors and transporters [9]. Glycome modulations are usually protein-specific, cell-specific,
site-specific and their mechanisms have been studied in detail; for a review, see [10]. Gly-
can modifications occur within tumors and their microenvironment (Figure 1). Abnormal
glycosylation also occurs in the liver after receiving signaling from tumors [9]. As a result,
modified glycosylation at the level of total N-glycome and acute-phase proteins measured
in the blood (serum or plasma) is a prominent feature of ovarian cancer (Table 2). Inflam-
matory processes being also part of tumor development, variations of IgG glycosylation in
the blood have also been noted.
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which, in turn, are downregulated upon OvCa progression as observed in recurrent pa-
tients [76]. Indeed, the presence of tri- and tetraantennary structures do inhibit the action 
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ing N-glycans [88]. Interestingly, bisecting GlcNAcylated biantennary structures were as-
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for increased sialylation in OvCa and was associated with tumor progression and metas-
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N-acetylglucosamine; red triangle, fucose; purple diamond, N-acetylneuraminic acid.
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Table 2. Serum total N-glycan biomarkers for ovarian cancer. ↑- upregulation, ↓- downregulation.
Glycosylation Trait Regulation in OvCa Reference
high-mannosylation ↓ [74,78,81–83]
hybrid structures ↓ [82]
branching
- mono-, biantennary ↓ [78,82]
- triantennary ↑ [74,76,78,81,82,84]
- tetraantennary ↑ [76,78,81,82]
bisection ↓ [76,83]↑ [85]
Sialylation
- asialylated structures ↓ [78]
- sialylated structures ↑ [74,76,78,81,86]
- ratio α2-3/α2-6 ↑ [73,81,84]
High-mannose N-glycans are downregulated in OvCa, the same was observed for gas-
tric cancer but not all types of cancer [74,78,81–83,87]. A decrease in hybrid structures was
reported as well [78,82]; however, neither the molecular cause nor the role of high-mannose
and hybrid N-glycans have been investigated in OvCa so far. Increased branching has been
associated with the early stages of OvCa invasion and metastasis [73,74,76]. Branching is
increased in OvCa due to the upregulation of mannoside acetylglucosaminyltransferases
4 and 5, genes that encode N-acetylglucosaminyltransferase IV (GnT-IV) and V (GnT-V).
They catalyze the addition of β1-4-GlcNAc and β1-6-GlcNAc on the N- glycan core [10,84].
Branching leads to the formation of many tri- and tetraantennary structures that are fully
galactosylated, which creates more substrates for the addition of terminal sialic acids [78].
An increase in tri- and tetraantennary structures is also associated with cancer progression
due to its negative correlation with bisecting structures, which, in turn, are downregulated
upon OvCa progression as observed in recurrent patients [76]. Indeed, the presence of
tri- and tetraantennary structures do inhibit the action of N-acetylglucosaminyltransferase
III (GnT III) that participate in the formation of bisecting N-glycans [88]. Interestingly,
bisecting GlcNAcylated biantennary structures were associated with resistance to pri-
mary chemotherapy [85]. Increased branching is the reason for increased sialylation in
OvCa and was associated with tumor progression and metastasis [76]. In human blood,
increases in the sialic acid linkage ratio α2,3-/α2,6 were measured even in early stage
OvCa [78] and correlate with increased ST3Gal I and ST6Gal I sialyltransferases measured
in ovarian cancer tissues [89]. Increased fucosylation was observed in the form of sialyl
LewisX (N-acetylneuraminic acid-α2-3-galactose-β1-4[fucoseα1-3] N-acetylglucosamine,
sLeX) epitopes [73,74,76,81,82] and correlates with the expression of the corresponding
α1-3-fucosyltransferase [90].
4.2. Immunoglobulin Glycosylation
Features of Immunoglobin G Fc glycosylation, especially galactosylation, reflect the
body’s physiological (age, gender, pregnancy) or pathological state [91,92]. Galactosylation
of complex-type N-glycans decreases with an increase in age, especially in women after
menopause [92]. Glycome modulations also occur in autoimmune diseases, infectious
diseases and malignancies including ovarian cancer [92,93]. These observed IgG glycan
changes are most likely due to the inflammation occurring in the tumor and surrounding
tissues as similar patterns are observed in rheumatoid arthritis [72]. In OvCa patients, a
decrease in the levels of IgG galactosylation is observed [52,73,75] (Table 3).
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Table 3. IgG glycopeptide biomarkers of ovarian cancer. ↑- upregulation, ↓- downregulation.
Potential Biomarker Regulation in OvCa References
agalactosylation ↑ [52,73,75,76,94]
core fucosylation ↑ [52,73]
IgG1 sialylation ↓ [52]
Ruhaak and coworkers found differentially expressed IgA, IgG, and IgM glycopep-
tides in OvCa, whereby the IgG1 glycopeptide bearing a bisected biantennary N-glycan at
asparagine-180 could efficiently discriminate EOC patients from healthy controls better
than other Ig types [94]. In a study on subclass-specific IgG glycosylation in OvCa, it was
found that IgG1 glycopeptide presented the greatest increase in agalactosylation and was
strongly associated with CA125. Of interest to note in this study is that IgG2 and IgG3
were analyzed separately. IgG3 was more sialylated and galactosylated than IgG2 and
consequently, was decreased in EOC patients [52].
4.3. Acute-Phase Proteins Glycosylation
Inflammation is a complex biological response to a stimulus such as infection, physical
injury, cell damage or malignancy. During an inflammatory response, cytokines released
from the site of inflammation travel to the hepatocytes to trigger an acute phase response
that causes modification in the secretion and glycosylation of acute-phase proteins (APPs)
(Table 4). The resultant concentration of APPs may increase by about 25% (positive acute-
phase proteins) or may reduce by 25% (negative acute-phase proteins) [95,96].
Table 4. Potential acute phase proteins N-glycan biomarkers for ovarian cancer. LeX, LewisX.
Acute Phase Glycoprotein Glycosylation Modulations Reference











The most abundant glycosylated APPs include haptoglobin, α-1 acid glycoprotein,
α-1 antitrypsin, anti-chymotrypsin, fibrinogen, complement, fetuin, and transferrin. The
changes in their N-glycan chains were studied for ovarian cancer by performing in-gel
digestion of the corresponding 2D gel bands [73,97]. An increase in branching, core-
fucosylation, sialylation, antennary fucosylation (named LewisX antigen, LeX) and anten-
nary fucosylation on a sialylated branch (named sialyl LeX antigen) were reported for
haptoglobin, α1-antichymotrypsin, α1-antitrypsin, α1-acid glycoprotein, C1 esterase in-
hibitor and hemopexin [73,97,98]. Interestingly, the N-glycomes of transferrin, C1 esterase
inhibitor, hemopexin and α2-HS-glycoprotein, which contain over 75% of biantennary
structures, were not significantly changed in OvCa [73,97].
4.4. Diagnostic Performances of Glycan-Based Biomarkers
Several research groups have evaluated the diagnostic performances of glycan biomark-
ers with cohort sizes ranging from 58 to 299 individuals (Table 5). The GLYCOV score,
integrating seven upregulated N-glycans and four downregulated N-glycans, demon-
strated better diagnostic performance characteristics than the routine test CA125. At
sensitivity of 97%, GLYCOV had a specificity of 98.4% for OvCa compared to the routine
test CA 125, which had a specificity of 88.9% [74]. In another study addressing benign
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ovarian diseases versus early stage OvCa, GLYCOV had a sensitivity of 95%, whereas
CA125 showed only 60% sensitivity [81].
Table 5. Diagnostic performances reported for glycan-based biomarkers.
Reference Biomarker Sensitivity/Specificity(%/%) Cohort Size
[74] GLYCOV(N-glycan score) 97/98.4 96
[81] GLYCOV(N-glycan score) 95/97 73
[78] CA-125 + sialic acid ratio 89.6/100 110
[77] N-glycan score 80–90/70–83 80
[83] N-glycan score 70/86.5 299
[94] IgG1 + IgA + IgM + CA125glycopeptide score 96.2/92.3 168
[75] IgG agalactosylation ratio + CA125 90/84.6 58
A combination of a ratio of α-2,3-linked/α-2,6-linked sialylated structures and CA 125
to stratify early- and late-stage OvCa yielded improved sensitivity and specificity of 89.6%
and 100%, respectively, compared to a sensitivity of 84.4% and specificity of 97% when
CA 125 was used alone [78]. The candidate glycan-based biomarker developed by Leis-
erowitz and coworkers had better performances than CA125 with sensitivity and specificity
ranging from 80–90% and 70–83%, respectively, whereas CA 125 had a sensitivity of
74% [77,83]. In another study of their working group, the IgG1 glycopeptide at asparagine
180 used in combination with CA125 improved the specificity from 86% to 95% in a vali-
dation cohort. When IgG1, IgA and IgM glycopeptides were combined with CA125, the
sensitivity and specificity reached 96.2% and 92.3%, respectively [94]. The Gu laboratory
showed that when IgG agalactosylation was used in addition to CA 125, the specificity
could be improved by 19.4%, while the sensitivity was maintained at 90% [75].
4.5. Glycan Biomarker Traits for Ovarian Cancer Staging and Monitoring
Previous findings have shown the association between various modulated glycosy-
lated structures with tumor growth and metastasis, which are key factors that inform
cancer staging. Follow-up studies have also shown either reduction or increase of mod-
ulated glycan traits towards the normal baseline levels upon treatment [76]. The glycan
traits that could potentially be helpful in OvCa staging and disease monitoring include
sLex, agalactosylation, galactosylation, branching (tri- and tetraantennary structures) and
bisecting structures. Several research groups have shown how these modulated features of
glycosylation in OvCa promote the invasiveness and metastasis of the disease [76,99,100].
It was previsouly shown that downregulation of high-mannose structures and upreg-
ulation of sialylated tri- and tetra-antennary structures containing mono- or difucosylation
differentially expressed in stage I and stage II of the epithelial OvCa patients. GLYCOV
value was able to discriminate OvCa stage I from stage II satisfactorily, whereas CA125 was
not able to [81]. Similarly, high-mannose, complex type asialylation and the bi-, tri- and
tetra-antennary sialylated structures are differentially expressed in early and late-stages
of OvCa. Moreover, a combination of sialic acid ratio and CA 125 stratified early and
late-stage OvCa patients with improved sensitivity and specificity of 89.6% and 100%,
respectively, when compared to a CA125 sensitivity of 84.4% and 97% specificity when
used as a single marker, as shown in Table 5 [78]. To affirm the place of glycan alterations
in the possible staging of OvCa, a study of an OvCa mouse model reported an increase in
sialylation with increasing tumor size, implying that sialylation is associated with OvCa
progression and, therefore, likely to be useful in staging [86]. These findings imply that
apart from its demonstrated potential to make an early diagnosis of OvCa, glycan-based
biomarkers could also find applications in monitoring disease progression and staging of
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OvCa, which could eliminate the need to carry out surgical procedures to obtain a biopsy
for histological examination and staging.
5. Challenges of Glycan Biomarker Discovery
Although there exist many opportunities in the field of glycomics with regard to
the discovery of biomarkers including those of OvCa, it has not been without challenges
that have delayed reaping the full benefits it offers. The glycome complexity is enormous
and had previously made it extremely complicated to undertake glycan biomaker studies.
However, the introduction of the new broad-spectrum high-throughput analytical tech-
nologies has sufficiently addressed the questions of identification and characterization
of the glycans. Consequently, there is increased output of research activities in OvCa
glycan-based biomarker discovery.
The very nature of OvCa heterogeneity is partly responsible for the delay in delivery
of an efficient screening and diagnostic strategy. Ovarian tumors manifest in different
phenotypes, molecular biology, etiology and tumor progression, each of them taking
different disease paths and with varied outcomes [101]. However, recent modernization
of high-throughput technologies has equipped glycomics research with high-precision
MS analyzers that are helping to unravel the heterogeneity dilemma. Consequently, high
possibilities of developing sets of glycan-based parameters that will aid in the screening
and early diagnosis of OvCa irrespective of their originality are now in sight. Variations in
sample handling (sample collection, shipment, storage and processing) are unlikely to be a
major source of result variability as others we have previously shown [102,103].
Several glycan-biomarker studies on OvCa have suffered from the fate of low statistical
power due to the often-low sample size used, leading to frequent less conclusive findings.
The problem of the small sample size is partly attributed to the low global prevalence rates
of OvCa, which may require a prolonged duration of research, especially in follow-up
studies. The problem of low prevalence means that a successful screening strategy must
meet an incredibly higher performance threshold to eliminate chances of unnecessary
surgeries due to false-positive results. The dangers of surgeries occasioned by false-
positive results may far outweigh the benefits that the patients derive from the expected
early diagnosis of OvCa as some surgeries may become complicated and even fatal. In
our view, the problem of sampling can be overcome by embracing the strategy of broad
multi-site collaborative studies that will attain high numbers of study participants quickly
and cut recruitment duration.
6. Conclusions
To conclude, the parallel development of instrumentation and high-throughput plat-
forms has allowed the discovery of new glycome-based biomarkers in recent years. The
ultimate aim being to find effective screening and early diagnostic strategies that will bring
about a reduction in mortalities associated with late diagnosis of OvCa. To date, much of
the research findings on glycomic-based OvCa biomarkers still fall within the discovery
phase. As methods are affordable and non-invasive, glycan-based biomarkers have the
potential to be clinically approved in the future but they are yet to be subjected through the
rigor of validation in multi-center studies in order to pave way for clinical approval.
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